Savara (SVRA) Non-Current Assets (2010 - 2026)
Savara (SVRA) reported Non-Current Assets of $12.4 million for Q1 2026, up 4.28% year-over-year from $11.9 million in Q1 2025, and up 4.74% on a QoQ basis from $11.8 million in Q4 2025.
Savara (SVRA) has 17 years of Non-Current Assets data on file, last reported at $12.4 million in Q1 2026.
- Quarterly Non-Current Assets rose 4.28% year-over-year to $12.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $49.7 million (up 5.72% YoY) and the FY2025 annual result came in at $11.8 million, up 10.01% from the prior year.
- Non-Current Assets rose to $12.4 million in Q1 2026 per SVRA's latest filing, from $11.8 million in the prior quarter.
- Across five years, Non-Current Assets topped out at $12.8 million in Q2 2025 and bottomed at $10.7 million in Q3 2022.
- The 5-year median for Non-Current Assets is $11.9 million (2025), against an average of $11.8 million.
- The widest annual swing landed in 2022, when Non-Current Assets declined 15.77%; it then grew 12.04% in 2023.
- Tracing SVRA's Non-Current Assets over 5 years: stood at $10.8 million in 2022, then rose by 7.34% to $11.6 million in 2023, then dropped by 7.51% to $10.7 million in 2024, then climbed by 10.01% to $11.8 million in 2025, then climbed by 4.74% to $12.4 million in 2026.
- Per Business Quant, the three latest SVRA Non-Current Assets figures stand at $12.4 million (Q1 2026), $11.8 million (Q4 2025), and $12.7 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 4.56 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | 62,953.78 |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 486.60 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | 5.83 Mn |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 30.30 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 14.75 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 22.66 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 910.24 Mn |
| 10 | Savara | 1.30 Bn | 1.30 Bn | - | 12.38 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 12.38 Mn |
| Dec 31, 2025 | 11.82 Mn |
| Sep 30, 2025 | 12.73 Mn |
| Jun 30, 2025 | 12.78 Mn |
| Mar 31, 2025 | 11.87 Mn |
| Dec 31, 2024 | 10.74 Mn |
| Sep 30, 2024 | 12.42 Mn |
| Jun 30, 2024 | 11.98 Mn |
| Mar 31, 2024 | 12.11 Mn |
| Dec 31, 2023 | 11.62 Mn |
| Sep 30, 2023 | 11.98 Mn |
| Jun 30, 2023 | 11.93 Mn |
| Mar 31, 2023 | 11.73 Mn |
| Dec 31, 2022 | 10.82 Mn |
| Sep 30, 2022 | 10.69 Mn |
| Jun 30, 2022 | 11.39 Mn |
| Mar 31, 2022 | 11.67 Mn |
| Dec 31, 2021 | 11.60 Mn |
| Sep 30, 2021 | 12.69 Mn |
| Jun 30, 2021 | 12.95 Mn |
| Mar 31, 2021 | 12.83 Mn |
| Dec 31, 2020 | 12.62 Mn |
| Sep 30, 2020 | 13.01 Mn |
| Jun 30, 2020 | 12.58 Mn |
| Mar 31, 2020 | 12.53 Mn |
| Dec 31, 2019 | 12.14 Mn |
| Sep 30, 2019 | 32.28 Mn |
| Jun 30, 2019 | 33.16 Mn |
| Mar 31, 2019 | 40.75 Mn |
| Dec 31, 2018 | 38.94 Mn |
| Sep 30, 2018 | 40.38 Mn |
| Jun 30, 2018 | 40.51 Mn |
| Mar 31, 2018 | 41.30 Mn |
| Dec 31, 2017 | 61.76 Mn |
| Sep 30, 2017 | 63.37 Mn |
| Jun 30, 2017 | 62.10 Mn |
| Mar 31, 2017 | 5.73 Mn |
| Dec 31, 2016 | 14.32 Mn |
| Sep 30, 2016 | 11.84 Mn |
| Jun 30, 2016 | 11.86 Mn |
| Mar 31, 2016 | 11.90 Mn |
| Dec 31, 2015 | 11.97 Mn |
| Sep 30, 2015 | 11.99 Mn |
| Jun 30, 2015 | 12.01 Mn |
| Mar 31, 2015 | 12.16 Mn |
| Dec 31, 2014 | 12.10 Mn |
| Sep 30, 2014 | 12.11 Mn |
| Jun 30, 2014 | 11.81 Mn |
| Mar 31, 2014 | 11.75 Mn |
| Dec 31, 2013 | 9.72 Mn |
| Sep 30, 2013 | 9.71 Mn |
| Jun 30, 2013 | 9.72 Mn |
| Mar 31, 2013 | 9.80 Mn |
| Dec 31, 2012 | 9.80 Mn |
| Sep 30, 2012 | 9.92 Mn |
| Jun 30, 2012 | 9.90 Mn |
| Mar 31, 2012 | 10.20 Mn |
| Dec 31, 2011 | 10.06 Mn |
| Sep 30, 2011 | 7.24 Mn |
| Jun 30, 2011 | 7.43 Mn |
| Dec 31, 2010 | 77,738.00 |